Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma

H Nakamura, A Mochizuki, T Shinmyo… - Anticancer …, 2010 - ar.iiarjournals.org
Background: Epidermal growth factor receptor (EGFR) mutational analysis has become
essential in determining a therapeutic strategy for lung cancer. This study validated the …

[HTML][HTML] Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies

Y Xiong, Y Bai, N Leong, TS Laughlin, PG Rothberg… - Diagnostic …, 2013 - Springer
Background The recent development of antibodies specific for the major hotspot mutations
in the epidermal growth factor receptor (EGFR), L858R and E746_A750del, may provide an …

Immunostaining with EGFR mutation–specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection …

X Fan, B Liu, H Xu, B Yu, S Shi, J Zhang, X Wang… - Human pathology, 2013 - Elsevier
Mutation analysis of epidermal growth factor receptor (EGFR) is essential in determining the
therapeutic strategy for lung adenocarcinoma. Immunohistochemical (IHC) staining with …

[HTML][HTML] Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry

M Yoshida, T Nagatomo, T Ohnishi… - Molecular and …, 2017 - spandidos-publications.com
Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR) improve the survival of
patients with lung adenocarcinoma, and determine the EGFR mutation status before …

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

AR Li, D Chitale, GJ Riely, W Pao, VA Miller… - The Journal of Molecular …, 2008 - Elsevier
Lung adenocarcinomas responsive to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors possess EGFR mutations and often increased EGFR copy number. We …

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for …

F Pinter, J Papay, A Almasi, Z Sapi, E Szabo… - The Journal of Molecular …, 2008 - Elsevier
The purpose of this study was to investigate whether detectable protein biomarker
overexpression is a prerequisite for the presence of increased gene copy number or …

Two allele-specific PCR assays for screening epidermal growth factor receptor gene hotspot mutations in lung adenocarcinoma

R Dahse, A Berndt, AK Dahse… - Molecular Medicine …, 2008 - spandidos-publications.com
In patients with non-small cell lung cancer, mutations in the EGFR tyrosine kinase domain
have been associated with improved response to tyrosine kinase inhibitors such as gefitinib …

Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R …

AN Seo, TI Park, Y Jin, PL Sun, H Kim, H Chang… - Lung Cancer, 2014 - Elsevier
Objectives Activating mutations in the epidermal growth factor receptor (EGFR) kinase
domain are correlated with dramatic clinical responses in non-small cell lung cancer …

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas

Q Pan, W Pao, M Ladanyi - The Journal of Molecular Diagnostics, 2005 - Elsevier
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor
(EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors …

[HTML][HTML] Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for …

Y Kato, N Peled, MW Wynes, K Yoshida… - Journal of Thoracic …, 2010 - Elsevier
Background: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC) predict better outcome to EGFR tyrosine kinase inhibitors. The most …